Research has suggested that Nesina and other Type 2 diabetes drugs called incretin mimetics may increase a patient’s risk for pancreatic cancer. Pancreatic cancer is extremely dangerous, with a five- year mortality rate greater than 95%.
Type 2 diabetics who were diagnosed with pancreatic cancer following treatment with Nesina may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To discuss filing a Nesina lawsuit with an attorney at Bernstein Liebhard LLP, please call (888) 994-5118.
Nesina (alogliptin) works by increasing levels of incretins in the digestive tract. These hormones control blood sugar by stimulating the pancreas to release insulin, especially after a meal. In recent years, a growing body of evidence has suggested that incretin mimetics like Nesina might be associated with a higher risk of pancreatic cancer.
The pancreas is an organ located behind the stomach and in front of the spine, which consists of both exocrine and neuroendocrine cells. Exocrine pancreatic cells produce enzymes that aid in digestion. Neuroendocrine pancreas cells (such as islet cells) make several hormones, including insulin and glucagon, which help control blood sugar levels.
Exocrine cells are where most pancreatic cancers originate. Because these tumors do not secrete hormones or cause much in the way of signs or symptoms, this type of pancreatic cancer is very rarely diagnosed in the early stages. Symptoms that do eventually appear are often vague or non-specific, and may include:
If you or loved one developed pancreatic cancer following treatment with Nesina, the attorneys at Bernstein Liebhard LLP are ready to help. To arrange for your free legal review, please call (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.